Reported Earnings • Jul 22
Second quarter 2026 earnings released: EPS: €0.016 (vs €0.016 in 2Q 2025) Second quarter 2026 results: EPS: €0.016 (in line with 2Q 2025). Revenue: €121.6m (up 17% from 2Q 2025). Net income: €8.40m (up 1.2% from 2Q 2025). Profit margin: 6.9% (down from 8.0% in 2Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.2% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 82% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth. Buy Or Sell Opportunity • Jul 01
Now 20% undervalued The stock has been flat over the last 90 days, currently trading at €2.58. The fair value is estimated to be €3.24, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 22% in 2 years. Earnings are forecast to grow by 83% in the next 2 years. お知らせ • Apr 29
Vimian Group AB (publ) to Report Fiscal Year 2026 Results on Feb 11, 2027 Vimian Group AB (publ) announced that they will report fiscal year 2026 results on Feb 11, 2027 Board Change • Dec 30
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Chairman of the Board Magnus Welander was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. お知らせ • Dec 24
Vimian Group AB (publ) (OM:VIMIAN) entered into an agreement to acquire I-Vet S.R.L. from the Franzini family. Vimian Group AB (publ) (OM:VIMIAN) entered into an agreement to acquire I-Vet S.R.L. from the Franzini family on December 23, 2025. The acquisition is financed with available funds. Following the acquisition, I-Vet will be integrated into Vimian’s Diagnostics segment, and CEO Daniele Franzini will continue to lead I-Vet as part of Vimian.
For the period ending December 31, 2024, I-Vet S.R.L. reported total revenue of €5.6 million and has 75 team members.
The acquisition is expected to be completed on or around March 2, 2026. The acquisition is expected to have marginal impact on earnings per share in the 2026 financial year. お知らせ • Oct 20
Vimian Group AB (publ) to Report Fiscal Year 2025 Final Results on Mar 19, 2026 Vimian Group AB (publ) announced that they will report fiscal year 2025 final results on Mar 19, 2026 お知らせ • Sep 23
Vimian Group AB (publ), Annual General Meeting, Apr 29, 2026 Vimian Group AB (publ), Annual General Meeting, Apr 29, 2026. お知らせ • Jun 13
Vimian Group AB (publ) (OM:VIMIAN) signed an agreement to acquire AllAccem Inc. Vimian Group AB (publ) (OM:VIMIAN) signed an agreement to acquire AllAccem Inc. on June 13, 2025. AllAccem Inc. had revenues of around $9 million for the twelve months ending April 2025, and an EBITDA margin significantly above the Vimian Group average. AllAccem will become part of Vimian’s MedTech segment and Jeffery Whiteford, founder and CEO of AllAccem Inc., will continue to lead the integrated business. The acquisition is expected to have marginal impact on earnings per share in the current financial year. The acquisition of AllAccem Inc. is expected to be completed on or around 13 June and is financed with available funds. お知らせ • Apr 30
Vimian Group AB (publ) Elects Pia Marions as Board Member Vimian Group AB (publ) at its Annual General Meeting held on 29 April 2025, Pia Marions was newly elected, as Board members for the time until the end of the next Annual General Meeting. お知らせ • Mar 14
Vimian Group AB (publ) to Report Q4, 2025 Results on Feb 12, 2026 Vimian Group AB (publ) announced that they will report Q4, 2025 results on Feb 12, 2026 Buy Or Sell Opportunity • Nov 07
Now 21% undervalued Over the last 90 days, the stock has risen 30% to €3.74. The fair value is estimated to be €4.71, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 31% in 2 years. Earnings are forecast to grow by 28,005% in the next 2 years. Reported Earnings • Oct 24
Third quarter 2024 earnings released: €0.004 loss per share (vs €0.016 profit in 3Q 2023) Third quarter 2024 results: €0.004 loss per share (down from €0.016 profit in 3Q 2023). Revenue: €87.6m (up 9.6% from 3Q 2023). Net loss: €2.13m (down 129% from profit in 3Q 2023). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 53 percentage points per year, which is a significant difference in performance. お知らせ • Oct 12
Vimian Group AB (publ), Annual General Meeting, Apr 29, 2025 Vimian Group AB (publ), Annual General Meeting, Apr 29, 2025. New Risk • Aug 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.1% average weekly change). Large one-off items impacting financial results. Shareholders have been diluted in the past year (14% increase in shares outstanding). Reported Earnings • Aug 16
Second quarter 2024 earnings released: EPS: €0.01 (vs €0.007 in 2Q 2023) Second quarter 2024 results: EPS: €0.01 (up from €0.007 in 2Q 2023). Revenue: €91.1m (up 12% from 2Q 2023). Net income: €4.87m (up 63% from 2Q 2023). Profit margin: 5.3% (up from 3.7% in 2Q 2023). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 55 percentage points per year, which is a significant difference in performance. Recent Insider Transactions • Jul 19
Chief Executive Officer of Nextmune recently sold €309k worth of stock On the 15th of July, Magnus Kjellberg sold around 100k shares on-market at roughly €3.09 per share. This transaction amounted to 2.8% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought €20m more than they sold in the last 12 months. Recent Insider Transactions • Jun 26
Director recently bought €931k worth of stock On the 19th of June, Gabriel Fitzgerald bought around 316k shares on-market at roughly €2.95 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €21m more in shares than they have sold in the last 12 months. お知らせ • May 23
Vimian Group AB (publ) Elects Magnus Welander to Board as Chairman of the Board Vimian Group AB (publ) at its Annual General Meeting held on 22 May 2024 announced that Magnus Welander was newly elected, as Board members for the time until the end of the next Annual General Meeting. Magnus Welander was elected as chairman of the Board. New Risk • May 16
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 25% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.3x net interest cover). Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Large one-off items impacting financial results. Shareholders have been diluted in the past year (14% increase in shares outstanding). Reported Earnings • May 02
First quarter 2024 earnings released First quarter 2024 results: EPS: €0.008. Revenue: €92.2m (up 4.7% from 1Q 2023). Net income: €3.50m (down 35% from 1Q 2023). Profit margin: 3.8% (down from 6.1% in 1Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Medical Equipment industry in Germany. Reported Earnings • Apr 12
Full year 2023 earnings released: EPS: €0.022 (vs €0.017 loss in FY 2022) Full year 2023 results: EPS: €0.022 (up from €0.017 loss in FY 2022). Revenue: €331.7m (up 18% from FY 2022). Net income: €9.84m (up €16.6m from FY 2022). Profit margin: 3.0% (up from net loss in FY 2022). The move to profitability was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Germany. お知らせ • Apr 05
Vimian Group AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 1.632566 billion. Vimian Group AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 1.632566 billion.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 65,302,624
Price\Range: SEK 25
Transaction Features: Regulation S; Rights Offering Reported Earnings • Feb 16
Full year 2023 earnings released: EPS: €0.022 (vs €0.017 loss in FY 2022) Full year 2023 results: EPS: €0.022 (up from €0.017 loss in FY 2022). Revenue: €331.8m (up 18% from FY 2022). Net income: €9.84m (up €16.6m from FY 2022). Profit margin: 3.0% (up from net loss in FY 2022). The move to profitability was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Buy Or Sell Opportunity • Feb 07
Now 24% undervalued Over the last 90 days, the stock has risen 19% to €2.43. The fair value is estimated to be €3.20, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 45% over the last 3 years. Meanwhile, the company became loss making. お知らせ • Dec 22
Vimian Group AB (publ) Announces CEO Changes Vimian Group AB (publ) appoints Patrik Eriksson Chief Executive Officer, effective 1 January 2024. Patrik Eriksson joins Vimian from Envista, a global dental company listed on NYSE, where he currently serves on the Executive Team as President of Nobel Biocare. Patrik Eriksson (56) has vast international experience from 25 years as general manager in the global medtech and life science industries. Since 2020, he is President of the dental company Nobel Biocare, part of Envista. Prior to that, he worked seven years at the global life sciences group Danaher (NYSE:DHR) as President of two of its medtech companies, KavoKerr and Ormco. He has led international organizations with more than 6,500 employees and revenues of USD 1.5 billion. He is a Swedish citizen and holds a M.Sc. in Business and Administration from the Stockholm School of Economics. Patrik Eriksson succeeds Fredrik Ullman whose departure at year-end was announced on 29 June 2023. Reported Earnings • Nov 09
Third quarter 2023 earnings released: EPS: €0.016 (vs €0.004 loss in 3Q 2022) Third quarter 2023 results: EPS: €0.016 (up from €0.004 loss in 3Q 2022). Revenue: €80.2m (up 13% from 3Q 2022). Net income: €7.43m (up €9.05m from 3Q 2022). Profit margin: 9.3% (up from net loss in 3Q 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany. お知らせ • Sep 26
Fidelio Capital acquired a 12% stake in Vimian Group AB (publ) for approximately SEK 240 million. Fidelio Capital acquired a 12% stake in Vimian Group AB (publ) for approximately SEK 240 million on September 21, 2023.
Fidelio Capital completed the acquisition of a 12% stake in Vimian Group AB (publ) on September 21, 2023. Recent Insider Transactions • Sep 24
Chairman of the board recently bought €20m worth of stock On the 21st of September, Gabriel Fitzgerald bought around 10m shares on-market at roughly €1.97 per share. This transaction amounted to 31% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Gabriel has been a buyer over the last 12 months, purchasing a net total of €20m worth in shares. Reported Earnings • Aug 18
Second quarter 2023 earnings released: EPS: €0.007 (vs €0.026 in 2Q 2022) Second quarter 2023 results: EPS: €0.007 (down from €0.026 in 2Q 2022). Revenue: €81.3m (up 21% from 2Q 2022). Net income: €2.99m (down 70% from 2Q 2022). Profit margin: 3.7% (down from 15% in 2Q 2022). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. お知らせ • Jun 30
Vimian Group AB (publ) Announces Fredrik Ullman Step Down as CEO Vimian Group AB (publ) announced that CEO Fredrik Ullman, following consultation with the Board, steps down as CEO. Fredrik Ullman has been the CEO of Vimian since its inception in 2020 and the CEO of its subsidiary Indical Bioscience since 2018. The recruitment process for a new CEO will be initiated immediately with Fredrik Ullman remaining as CEO in the interim and at the latest until year-end. The recruitment process for a new CEO will be initiated immediately and Fredrik Ullman will remain as CEO in the interim. お知らせ • Jun 03
Vimian Group AB (Publ) Elects Robert Belkic as New Board Member Vimian Group AB (publ) at the Annual General Meeting 2 June 2023, announced Robert Belkic was newly elected, as Board members for the time until the end of the next Annual General Meeting. Reported Earnings • May 05
Full year 2022 earnings released: €0.017 loss per share (vs €0.019 profit in FY 2021) Full year 2022 results: €0.017 loss per share (down from €0.019 profit in FY 2021). Revenue: €281.3m (up 62% from FY 2021). Net loss: €6.74m (down 202% from profit in FY 2021). Recent Insider Transactions • Mar 13
Chief Executive Officer recently bought €94k worth of stock On the 9th of March, Fredrik Ullman bought around 40k shares on-market at roughly €2.36 per share. This transaction amounted to 2.1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Fredrik's only on-market trade for the last 12 months. Reported Earnings • Mar 09
Full year 2022 earnings released: €0.017 loss per share (vs €0.019 profit in FY 2021) Full year 2022 results: €0.017 loss per share (down from €0.019 profit in FY 2021). Revenue: €287.8m (up 66% from FY 2021). Net loss: €6.74m (down 202% from profit in FY 2021). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Valuation Update With 7 Day Price Move • Mar 04
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to €2.01, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 25x in the Medical Equipment industry in Europe. Total loss to shareholders of 55% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €2.67 per share. Buying Opportunity • Feb 28
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 21%. The fair value is estimated to be €2.89, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 58% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 13% per annum. Earnings is also forecast to grow by 43% per annum over the same time period. Valuation Update With 7 Day Price Move • Jan 14
Investor sentiment improved over the past week After last week's 20% share price gain to €2.79, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 28x in the Medical Equipment industry in Europe. Total loss to shareholders of 59% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €2.82 per share. Valuation Update With 7 Day Price Move • Dec 20
Investor sentiment deteriorated over the past week After last week's 19% share price decline to €2.66, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 28x in the Medical Equipment industry in Europe. Total loss to shareholders of 62% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €3.02 per share. Reported Earnings • Nov 17
Third quarter 2022 earnings released Third quarter 2022 results: Revenue: €72.4m (up 75% from 3Q 2021). Net loss: €1.62m (loss widened 488% from 3Q 2021). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany. Board Change • Nov 16
High number of new and inexperienced directors There are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. No experienced directors. No highly experienced directors. Director Theodor Bonnier is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Valuation Update With 7 Day Price Move • Oct 29
Investor sentiment improved over the past week After last week's 17% share price gain to €3.00, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 27x in the Medical Equipment industry in Germany. Total loss to shareholders of 67% over the past year. お知らせ • Oct 25
Vimian Group AB (publ), Annual General Meeting, Jun 01, 2023 Vimian Group AB (publ), Annual General Meeting, Jun 01, 2023. Valuation Update With 7 Day Price Move • Sep 19
Investor sentiment deteriorated over the past week After last week's 18% share price decline to €2.75, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 25x in the Medical Equipment industry in Germany. Total loss to shareholders of 70% over the past year. お知らせ • Sep 09
Vimian Appoints Carl-Johan Ehn as General Counsel and Member of the Vimian Group Management Team Vimian appointed Carl-Johan Ehn as General Counsel and member of the Vimian Group management team as of 7 September 2022. Carl-Johan Ehn has over two decades of experience from international law in the global pharmaceutical industry at Zoetis and Pfizer, as well as from Mannheimer Swartling law firm. He joins Vimian from animal health company Zoetis where he held various leading positions over the past nine years, most recently as Chief Counsel for its international operations. The General Counsel is a new addition to the Vimian Group management team and will focus on supporting the company in the execution of commercial strategies, and ensuring high corporate governance and compliance standards. Carl-Johan Ehn joined Vimian on 15 August and was appointed member of the Vimian Group management team on 7 September. Valuation Update With 7 Day Price Move • Sep 03
Investor sentiment deteriorated over the past week After last week's 18% share price decline to €3.01, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 27x in the Medical Equipment industry in Germany. Total loss to shareholders of 70% over the past year. Reported Earnings • Aug 25
Second quarter 2022 earnings released Second quarter 2022 results: Revenue: €68.6m (up 74% from 2Q 2021). Net income: €9.99m (up €13.1m from 2Q 2021). Profit margin: 15% (up from net loss in 2Q 2021). The move to profitability was driven by higher revenue. Over the next year, revenue is forecast to grow 32%, compared to a 7.8% growth forecast for the Medical Equipment industry in Germany. お知らせ • Aug 03
Vimian Group AB (publ) (OM:VIMIAN) acquired Heiland Gmbh. Vimian Group AB (publ) (OM:VIMIAN) acquired Heiland Gmbh on August 1, 2022. Heiland a family-owned business that has annual revenues of around €1.5 million.
Vimian Group AB (publ) (OM:VIMIAN) completed the acquisition of Heiland Gmbh on August 1, 2022. お知らせ • Jul 15
Vimian Group AB (publ) Appoints Carl-Johan Zetterberg Boudrie as CFO and Member of Management Team Vimian Group appoints Carl-Johan Zetterberg Boudrie as new Chief Financial Officer and intends to continue to build out its finance organisation to support Vimian's growth journey. Carl-Johan assumes the position as CFO and member of the Vimian Group management team, and succeeds Henrik Halvorsen who has decided to focus on his role as CFO of Vimian's Specialty Pharma segment Nextmune. Carl-Johan Zetterberg Boudrie has extensive experience as CFO in publicly traded companies as well as from senior leadership positions within business development, M&A and management consulting at Beijer Electronics, SEB and Capgemini. The past six years, Carl-Johan held positions as CFO and subsequently CEO of the technology company Doro AB (publ) listed on Nasdaq Stockholm. Most recently, he was CEO of Careium AB (publ), a spin-off from Doro AB. Carl-Johan Zetterberg Boudrie succeeds Henrik Halvorsen who has held dual positions as CFO of Vimian and CFO of Vimian's Specialty Pharma segment Nextmune, and who now decided to focus solely on his position at Nextmune. Henrik Halvorsen will remain as Vimian's CFO until Carl-Johan Zetterberg Boudrie has assumed his position. Carl-Johan will assume the position as CFO of Vimian as soon as a successor has been appointed for his current position. Buying Opportunity • Jun 16
Now 26% undervalued after recent price drop Over the last 90 days, the stock is down 12%. The fair value is estimated to be €6.14, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 89% over the last year. Meanwhile, the company has become profitable. Revenue is forecast to grow by 73% in 2 years. Earnings is forecast to grow by 1,371% in the next 2 years. Reported Earnings • May 06
Full year 2021 earnings released: EPS: €0.019 (vs €0.18 in FY 2020) Full year 2021 results: EPS: €0.019 (down from €0.18 in FY 2020). Revenue: €173.4m (up 143% from FY 2020). Net income: €6.59m (down 88% from FY 2020). Profit margin: 3.8% (down from 74% in FY 2020). Over the next year, revenue is forecast to grow 51%, compared to a 11% growth forecast for the industry in Germany. Board Change • Apr 27
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Director Theodor Bonnier is the most experienced director on the board, commencing their role in 2021. Independent Director Mikael Dolsten was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. お知らせ • Apr 05
Vimian Group AB (publ) (OM : VIMIAN) acquired VerticalVet, LLC. Vimian Group AB (publ) (OM : VIMIAN) acquired VerticalVet, LLC on April 1, 2022.
Vimian Group AB (publ) (OM : VIMIAN) completed the acquisition of VerticalVet, LLC on April 1, 2022. Reported Earnings • Mar 11
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Full year 2021 results: EPS: €0.017 (down from €0.18 in FY 2020). Revenue: €178.2m (up 150% from FY 2020). Net income: €6.59m (down 88% from FY 2020). Profit margin: 3.7% (down from 74% in FY 2020). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 2.2%. Over the next year, revenue is forecast to grow 36%, compared to a 11% growth forecast for the industry in Germany. お知らせ • Feb 04
Vimian Group AB (publ) (OM:VIMIAN) signed an agreement to acquire Kahu Vet Group for €22.5 million. Vimian Group AB (publ) (OM:VIMIAN) signed an agreement to acquire Kahu Vet Group for €22.5 million on February 3, 2022. The consideration consists of upfront payment of €12.1 million and potential earnout of €10.4 million subject to financial performance over three years. The consideration of €12.1 million id financed with available funds. For the year 2021, Kahu Vet Group reported revenue of approximately €8.5 million and EBITDA of approximately €1.6 million. The transaction is expected to close on or around March 1, 2022. Selling management has committed to reinvest part of the proceeds in Vimian shares. Reported Earnings • Dec 01
Third quarter 2021 earnings: EPS in line with analyst expectations despite revenue beat Third quarter 2021 results: €0.001 loss per share. Revenue: €41.5m (flat on 3Q 2020). Net loss: €275.0k (flat on 3Q 2020). Revenue exceeded analyst estimates by 1.8%. Over the next year, revenue is forecast to grow 35%, compared to a 13% growth forecast for the industry in Germany. Valuation Update With 7 Day Price Move • Nov 27
Investor sentiment deteriorated over the past week After last week's 22% share price decline to €7.50, the stock trades at a forward P/E ratio of 85x. Average forward P/E is 39x in the Medical Equipment industry in Germany. Simply Wall St's valuation model estimates the intrinsic value at €5.28 per share. Valuation Update With 7 Day Price Move • Nov 27
Investor sentiment deteriorated over the past week After last week's 22% share price decline to €7.50, the stock trades at a forward P/E ratio of 85x. Average forward P/E is 39x in the Medical Equipment industry in Germany. Simply Wall St's valuation model estimates the intrinsic value at €5.28 per share. 
